Factset League Tables YTD-September

Hey all, just thought it'd be interesting to post the US and Global M&A League Tables for YTD-September from FactSet.

US League Table
USA M&A League Table
Global League Table
Global M&A League Table
Keep in mind that league tables are NOT 100% accurate (aka please don't turn this into another ranking thread). Also, note that the transaction value only includes disclosed transaction values, while total deals includes all announced deals (including undisclosed transaction values).

Comments (73)

  • Analyst 2 in IB - Cov
Oct 2, 2021 - 11:28am

Memes aside, RBC is doing very well in the US, but their lack of global presence is really showing (only $16B more in disclosed transaction value globally than in the US). Also surprised that Lazard is so low in US league tables.

Oct 4, 2021 - 3:28pm
PeRmAnEnTiNtErN, what's your opinion? Comment below:

Yeah suprised by Lazard too. But Qualayst is doing some good shit. 

  • Analyst 2 in IB - Gen
Oct 2, 2021 - 11:35am

Moelis does a lot more sponsor advisory than strategic advisory compared to other EBs, and sponsor transactions tend to have undisclosed values a lot more, hence why Moelis's total disclosed value is a lot lower. Looking at the data, only 55% of Moelis's transactions have disclosed values, compared to 62% for Lazard, 69% for Evercore, 72% for PJT, and 83% for CVP and PWP.

  • Intern in IB - Cov
Oct 2, 2021 - 12:34pm

What matters more? Deal count or value rankings?

  • Analyst 2 in IB - Cov
Oct 2, 2021 - 12:41pm

Both. What really matters is your deal reps and exposure as an analyst (essentially deal count/IB analyst class size could serve as a decent proxy). I can tell you that deal size really doesn't matter that much and doesn't mean a better analyst experience. I'm at an EB that does everything from the $100M sell side to the mega-cap deal, and I've generally found that deals around the $700-$1.5B range have been the most enjoyable deals to work on.

  • Intern in IB-M&A
Oct 2, 2021 - 3:44pm

Moelis usually isn't that high in league tables. Their bread and butter has always been MM to mid-cap sponsor sell-sides, and have always been a volume shop like Jefferies or Lazard doing way more deals than the PJT/CVP-type firms. 

Most Helpful
  • Analyst 2 in IB - Gen
Oct 2, 2021 - 1:47pm

Very interesting, thanks for posting.

- Evercore seems to have solidified its status as "the Goldman of independent advisory firms" 

- Jefferies is killing it, seems like it's solidly established itself below CS in North America over the past couple of years. International presence is still weaker than the BBs though. 

- Allen & Co, Qatalyst, and LionTree are absolutely killing it in TMT

- WF's M&A deal flow still doesn't seem to have picked up compared to the past few years

- Greenhill has seemed to completely dropped off. I don't think they've been in top 50 in league tables since 2018 or so.

  • Intern in IB-M&A
Oct 3, 2021 - 7:05pm

Yeah WF is a lower than I thought they'd be. I always thought of them as below RBC by a bit, but not by that much.

  • Analyst 1 in IB - Gen
Oct 4, 2021 - 1:13pm

Wells is a financing bank, and until recently has been very content to stay there. Scharf has been pushing us to gain more M&A share, but that won't happen overnight

  • Intern in IB-M&A
Oct 2, 2021 - 5:14pm

Interesting to see the difference in number of deals between the EBs. You have PJT with 36 deals so far all the way to Rothschild, which may not be an EB in the US but I guess counts as a global EB, with 323 deals.

Oct 5, 2021 - 3:40pm
stu234, what's your opinion? Comment below:

driven by their balance sheet. they'll provide financing for a deal, do no actual M&A advisory, but ask for M&A credit (and usually give better financing terms for it). so transaction value isn't as good a proxy as revenues if you are looking for a metric that implies deal flow or potential bonus comp.

  • Intern in IB-M&A
Oct 2, 2021 - 5:53pm

Completely off-topic but didn't BofA's IB division drop the ML name in 2019? If so, when will that name change start to reflect in the Industry (aka FactSet stop using BofA ML, people stop shortening BofA to BAML on WSO, etc)? Just curious because I feel like by 2014/15 few people used Wachovia to refer to WF's IBD brand. 

  • Summer Associate in IB-M&A
Oct 2, 2021 - 5:57pm

I think it is slowly happening. The BAML name is a lot more sticky as BofA's kept it around a lot longer than WF kept Wachovia (I believe WF kept the Wachovia name for only 3 years), but I think there's been a very gradual transition (anecdotally at my BB fewer and fewer of the senior people are calling BofA by Merrill). Give it maybe 5 or more years and I think the BAML name may be gone.

  • Prospect in IB - Cov
Oct 2, 2021 - 9:45pm

Incredibly insightful, I really appreciate it! Could you maybe do the same thing for industries, specifically Tech and Healthcare?

  • Analyst 1 in IB - Cov
Oct 3, 2021 - 8:51am

Could anybody please pull league tables from other sources, eg. Bloomberg, to complement what was already posted?

  • Analyst 2 in IB - Gen
Oct 3, 2021 - 7:09pm

Although it was already well known in Rothschild's case, it's interesting to see Lazard's disparity between their global M&A deal flow vs their U.S. deal flow.

  • Intern in IB-M&A
Oct 3, 2021 - 10:08pm

Just thought it'd be interesting to post these 2007 Mergermarket M&A league tables I found.


2007 Global M&A


2007 US M&A

  • Intern in IB-M&A
Oct 3, 2021 - 10:13pm

Interesting, thanks for posting! Surprising to see how little has changed, with Barc today roughly where Lehman was, and BofA roughly where Merrill was. Did not know that Wachovia was as strong as it was (for some reason I always had the impression Wachovia was where WF roughly is today back then). Interesting that Greenhill completely fell off, and Jeff and Guggenheim really were nowhere pre-GFC.

  • Analyst 2 in IB - Cov
Oct 3, 2021 - 10:25pm

Seems like there was also a much larger distinction between BB and everything else back then. The BB field was pretty tight globally back then, with 1-9th occupied by BBs and all of them above $600B in transaction volume.

Oct 4, 2021 - 12:58pm
NewIndustryHorizon, what's your opinion? Comment below:

This was an interesting post. Know a few people who were at Bear Stearns/CIBC back then (had no clue CIBC did fairly well back then honestly, Bear Stearns was a scrappy banker. A former IB analyst (left finance after working at Bear Stearns) said it was a very scrappy bank vs bigger banks. Often let hard workers get to better departments internally vs. hiring external candidates. Heard that although Blackstone M&A often wasn't in the top echelon of banks in M&A fees, it was one of the hardest interviews/positions to land. Their exits were absurd vs. most of the street.

  • Associate 1 in IB - ECM
Oct 8, 2021 - 12:59pm

I've never heard too much negative feedback on BAML.  Citi gets a bad rep because they 'self own' somewhat consistently.  Lots of stories about pitches destined to fail, dropped balls, missing out on deals for silly reasons (an MD repeatedly mispronouncing the client's name from one story I've heard).  They also have below-average internal management - it can take months to get approval from finance / HR to replace an analyst who leaves for PE - even when most of a team leaves at the same time (which they've had to deal with).

Also, at least amongst (some of) the junior class, they jokingly call themselves 'Shitty Bank', which comes from the above + the fact that they routinely try to compete with GS/MS/JPM and lose out on mandates.

Bankers aren't usually the happiest bunch, but the Citi guys I've met seem to be some of the least happy - all of the pain of banking, with worse institutional support, and a handicap on exits and comp vs. the banks they consider their peers.

Oct 9, 2021 - 1:38pm
Legion42, what's your opinion? Comment below:

Citi pre 2008 had a pretty good reputation if I recall correctly. I think they were on par with JPM but obviously the mortgage crisis hit them hard and they never bounced back. 

  • Prospect in IB - Gen
Oct 4, 2021 - 11:48am

For more info here is the dealogic league tables as well (covers both global and us): http://graphics.wsj.com/investment-banking-scorecard/

Oct 4, 2021 - 1:20pm
SafariJoe, what's your opinion? Comment below:

Anonymous Monkey

Hey all, just thought it'd be interesting to post the US and Global M&A League Tables for YTD-September from FactSet.

US League Table

USA M&A League TableGlobal League TableGlobal M&A League TableKeep in mind that league tables are NOT 100% accurate (aka please don't turn this into another ranking thread). Also, note that the transaction value only includes disclosed transaction values, while total deals includes all announced deals (including undisclosed transaction values).

Goldman, wins again!

SafariJoe, wins again!
  • Prospect in IB - Cov
Oct 4, 2021 - 3:52pm

Thanks for this. Could anyone share the standings by industry - Tech, HC?

Oct 5, 2021 - 10:26am
user_276, what's your opinion? Comment below:

Is there a place to see the median deal or something to that effect for different firms? I feel like a lot of these may be thrown off by a handful of big deals

  • Intern in IB - Gen
Oct 6, 2021 - 12:08pm

Goldman had an avg. value of ~$3bln/deal YTD, compared to JPM's ~2.6bln/deal and MS' ~$3.3bln/deal. I think it's honestly fine to divide out the deal value by # of deals; all the top 3 banks hunt for 'whales,' and will be on 90-100% of mega caps. But also, they're all on the ~$100-1b deals -- at least for JPM & GS since those two have the Regional IB & Cross Markets groups to break into the mid-market. To the extent that deal size is influencing anything, it's the placement of the EBs imo. The gap between JP and Citi, for example, is really a lot of deal flow since Citi's average value per deal is about the same ($413,320 / 142 ~= 2.9b) as JPM's.

  • Prospect in IB - Gen
Oct 6, 2021 - 2:02pm

It seems PWP is having a really good year. Interested to hear if people think this is a one-off or if this will be a sustained thing

Oct 6, 2021 - 11:57pm
ECM GUY, what's your opinion? Comment below:

Sustained, they consistently do more and more deals despite such a small head count. With expected growth it'll be interesting to see what they evolve into.

Oct 8, 2021 - 2:13pm
lololol28, what's your opinion? Comment below:

Vitae dicta consectetur est aliquid quo cum dolorem. Est odio facilis rem mollitia veritatis. Repellat facere dolores voluptas et vel. Consequuntur est incidunt similique qui ea fugiat reiciendis.

Enim voluptates et qui eius nobis sed. Sint fugiat laborum et consequuntur. Maxime magni libero sint aut ad voluptas maxime occaecati. Repudiandae accusantium impedit minus eligendi aut vero molestiae fugiat. Nisi excepturi nemo id laboriosam.

Aperiam totam quia totam necessitatibus dolores ut. Neque debitis nulla neque ea expedita deleniti porro. Minima et error necessitatibus sit est laudantium. Aperiam quaerat omnis non et. Cumque animi dolorem sed.

Aliquid ut temporibus odio qui. Similique voluptatibus quia ducimus vel eveniet nisi quasi ipsum. Excepturi et blanditiis accusantium excepturi quia quaerat quam. Sint autem nemo explicabo. Excepturi enim laborum rerum quibusdam.

  • Associate 1 in IB-M&A
Oct 8, 2021 - 3:23pm

Inventore mollitia ea autem. Id saepe aut tenetur officiis sint maxime. Beatae dolorem ut et odit animi tempora.

Quisquam dicta magni libero et voluptates. Non et dicta aspernatur. Saepe magni explicabo deserunt et qui ea fuga.

Ut voluptate molestiae et est. Ut itaque aut accusantium assumenda voluptatum. Beatae excepturi sit earum libero. Sunt vero ad qui et aliquam. Reiciendis officiis iste harum nulla fugit sunt. Exercitationem illo sint voluptas et doloribus laborum.

Start Discussion

Total Avg Compensation

May 2022 Investment Banking

  • Director/MD (9) $661
  • Vice President (35) $399
  • Associates (179) $247
  • 2nd Year Analyst (109) $161
  • 3rd+ Year Analyst (17) $156
  • 1st Year Analyst (347) $148
  • Intern/Summer Associate (73) $146
  • Intern/Summer Analyst (272) $91